Crinetics Pharmaceuticals, Inc.
CRNX
Rank in Stocks
#2248
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical... Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Share Price
$84.95
Last synced: 2026-09-01
Market Cap
$9.00B
Change (1 day)
0.00%
Change (1 year)
100.12%
Country
US
Trade Crinetics Pharmaceuticals, Inc. (CRNX)
Category
Healthcare
P/S ratio for Crinetics Pharmaceuticals, Inc. (CRNX)
P/S ratio as of October 2026 TTM: 213.80
According to Crinetics Pharmaceuticals, Inc. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 213.80. At the end of 2023 the company had a P/S ratio of 514.87.
P/S ratio history for Crinetics Pharmaceuticals, Inc. from 2016 to 2026
P/S ratio at the end of each year
| Year | P/S Ratio | Change |
|---|---|---|
| 2026 (TTM) | 213.80 | -94.62% |
| 2024 | 3.98K | 672.12% |
| 2023 | 514.87 | 156.39% |
| 2022 | 200.82 | -80.18% |
| 2021 | 1.01K | -83.26% |
| 2020 | 6.05K | 1,090.15% |
| 2019 | 508.42 | 239.01% |
| 2018 | 149.97 | -9.84% |
| 2017 | 166.33 | -71.20% |
| 2016 | 577.51 | 0.00% |
P/S ratio for similar companies or competitors
| Company | P/S Ratio | P/S Ratio Difference | Country |
|---|---|---|---|
| 10.02 | -95.31% |
US
|
|
| 40.55 | -81.03% |
US
|
|
| 3.96 | -98.15% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -95.25% |
NL
|
